BOEHRINGER INGELHEIM
Bruno Rizzuti joined Boehringer Ingelheim in 2014 and took up his role as Head of Data Management in 2020 . " I moved into the pharmaceutical industry when I was very young ," says Rizzuti . " I had been working as a consultant on analytical processing systems , working with many clients in the pharma industry – which is how I got to know the industry so well – and then moved to Boehringer Ingelheim ."
Inclusiveness in the industry has been a draw for Rizzuti , being one of the main reasons he joined the industry . “ Big Pharma companies listen to their employees , as well – this is something you can immediately tell when you join a pharma company ,” says Rizzuti . “ Whether at Boehringer Ingelheim or another company , the standard in the industry is that the employee ' s voice is heard , based on the notion that this is important because happy people give better results ."
Innovation is another attractive , industrywide aspect of the profession , according to Rizzuti . " You cannot survive in pharma if you don ' t innovate . You must innovate in new treatments and in new therapeutic areas . This is an industry that has innovation at its essence . And that also makes it a wonderful place to grow ; you always have new challenges ."
BRUNO RIZZUTI TITLE : HEAD OF DATA MANAGEMENT
INDUSTRY : PHARMACEUTICAL MANUFACTURING
LOCATION : BARCELONA , SPAIN
Bruno Rizzuti is currently the
Head of Data Management & Data Engineering at Boehringer- Ingelheim with an extra passion about working culture , data-driven mindsets and technology scouting . His studies include Data Engineering , Data Science , Project Management and a little bit of Economics . In his free time , he exercises , studies technology , reads and plays videogames .
With over a decade of experience in Data & Analytics in the Big Pharma Industry and viscerally passionate about technology , he has his focus every day in what he considers the two most valuable assets of any organisation : People and Data .
52,000
Global workforce
130 Markets served by Boehringer Ingelheim
EXECUTIVE BIO